Targeting CK2 eliminates senescent cells and prolongs lifespan in Zmpste24-deficient mice

Jie Zhang1,2,3, Pengfei Sun1, Zhuping Wu1

  • 1Guangdong Key Laboratory of Genome Stability and Human Disease Prevention, Carson International Cancer Center, Department of Biochemistry & Molecular Biology, School of Basic Medical Sciences, Shenzhen University Medical School, Shenzhen, 518055, China.

PubMed

Insights

Senolytics clear senescent cells to treat aging. This study found 4,5,6,7-tetrabromo-2-azabenzamidazole (TBB) clears senescent cells by targeting DNA damage response, extending lifespan in mice.

Area of Science:

  • Cellular senescence
  • Aging research
  • DNA damage response

Background:

  • Senescent cell clearance is a promising strategy for age-related diseases.
  • Senolytics are uncommon, and their mechanisms are poorly understood.
  • Genomic instability is explored as a potential senolytic target.

Purpose of the Study:

  • Investigate genomic instability as a senolytic target.
  • Identify novel senolytic compounds and their mechanisms of action.
  • Evaluate the therapeutic potential of identified compounds in a progeroid model.

Main Methods:

  • Screened kinase inhibitors involved in DNA damage response (DDR).
  • Utilized Zmpste24-/- mouse embryonic fibroblasts (a progeroid model).
  • Assessed apoptosis induction and lifespan extension in Zmpste24-deficient mice.

Main Results:

  • Identified 4,5,6,7-tetrabromo-2-azabenzamidazole (TBB) as a senolytic compound.
  • TBB inhibits casein kinase 2 (CK2), disrupting heterochromatin remodeling and accelerating apoptosis in senescent cells.
  • TBB treatment alleviated progeroid features and extended lifespan in Zmpste24-deficient mice.

Conclusions:

  • TBB is a novel senolytic compound targeting CK2 and DDR.
  • Disrupting heterochromatin remodeling accelerates senescent cell apoptosis.
  • TBB shows therapeutic potential for age-related diseases and lifespan extension.